详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Preparation and characterization of a polyclonal antibody against PTEN-Long.

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ EI

作者：

机构： [1]Department of Urology, West China Hospital, Sichuan University, Chengdu, China. [2]Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. [3]Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, China. [4]Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.

出处：

DOI：

ISSN：

关键词： characterization polyclonal antibody PTEN-L verification

摘要：

Phosphatase and tensin homolog-long (PTEN-L) is a translational isoform of PTEN, which exists in both intracellular and extracellular locations. Previous studies demonstrated that PTEN-L could inhibit oncogenesis due to its lipid phosphatase activity. However, recent studies found that PTEN-L could promote the proliferation of some types of cancer cells. Moreover, as a protein phosphatase, PTEN-L can suppress mitophagy by counteracting PTEN-induced putative kinase protein 1 (PINK1)-Parkin-mediated ubiquitin phosphorylation, namely, PTEN-L is critical for exploring the mitophagy progression and the treatment of mitochondrial diseases. Accounting for the critical functions of PTEN-L, its antibody can be used for the treatment or prognosis of tumors and mitochondrial diseases. Currently, the commercial antibody of PTEN-L is not available. In our study, the recombinant PTEN-L protein was expressed in Escherichia coli BL21 and used as an antigen to immunize Japan's big-eared white rabbit for the preparation of polyclonal antibody. The PTEN-L protein can be captured by PTEN-L antibody specifically and effectively. Taken together, a PTEN_L antibody is a valuable tool for further exploring the function of PTEN-L in oncogenesis and mitochondrial diseases, and it would be a new choice for the prognosis or treatment of cancer and mitochondrial diseases.© 2021 International Union of Biochemistry and Molecular Biology, Inc.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 4 区工程技术

小类 | 4 区生化与分子生物学 4 区生物工程与应用微生物

最新[2023]版：

大类 | 4 区生物学

小类 | 4 区生化与分子生物学 4 区生物工程与应用微生物

第一作者：

第一作者机构： [1]Department of Urology, West China Hospital, Sichuan University, Chengdu, China. [2]Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Urology, West China Hospital, Sichuan University, Chengdu, China. [2]Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. [4]Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. [*1]Department ofCardiology,West ChinaHospital, Sichuan University, Guoxue Xiang #37, Chengdu, Sichuan 610041, China. [*2]Department of Urology, Institute ofUrology,WestChina Hospital, Sichuan University, 88 SouthKeyuan Road,Chengdu, 610041, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]单纯疱疹病毒胸苷激酶多克隆抗体的制备 [2]An automated dose verification software for brachytherapy [3]Evaluation of Proton Therapy Accuracy Using a PMMA Phantom and PET Prediction Module. [4]The development and verification of nomogram to predict the survival prognosis of patients with esophageal squamous cell carcinoma [5]Preliminary study of clinical application on IMRT three-dimensional dose verification-based EPID system [6]利用ArcCHECK在实际机架角与零机架角的IMRT剂量验证结果比较 [7]Experimental verification of a 3D in vivo dose monitoring system based on EPID [8]放射治疗记录与验证系统质量控制指南 [9]A Beam Projection-Based Modified Gamma Analysis Scheme for Clinically Interpretable Pre-Treatment Dose Verification [10]Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.